|
|
|
10.11.25 - 22:33
|
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight (GlobeNewswire EN)
|
|
|
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it has regained exclusive distribution rights for TULSA-PRO® in Canada from Knight Therapeutics Inc. (“Knight”)....
|
|
|
|
|
|
|
|
|
|
|
30.10.25 - 22:18
|
Knight Therapeutics Announces Launch of JORNAY PM™ in Canada (GlobeNewswire EN)
|
|
|
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ (methylphenidate HCI extended-release capsules) in Canada. JORNAY PM™ is an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children 6-12 years of age.1...
|
|
|
30.10.25 - 12:33
|
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina (GlobeNewswire EN)
|
|
|
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory approval and has launched MINJUVI® in Argentina. Knight obtained approval from the Argentinian health regulatory agency, ANMAT, for MINJUVI® (tafasitamab) in combination with lenalidomide, followed by MINJUVI® monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell transplantation (ASCT)....
|
|
|
30.10.25 - 12:33
|
Notice of Knight Therapeutics′ Third Quarter 2025 Results Conference Call (GlobeNewswire EN)
|
|
|
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2025 financial results on Thursday, November 6, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call....
|
|
|
|
|
|
|
|
|
|
|
20.08.25 - 13:33
|
Knight Announces Normal Course Issuer Bid (GlobeNewswire EN)
|
|
|
MONTREAL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB"). Pursuant to the NCIB, the Company proposes to purchase, from time to time over the next 12 months, if considered advisable, up to 3,000,000 common shares of the Company, being approximately 3% of its 99,653,265 common shares issued and outstanding as of August 8, 2025. Purchases may commence on August 22, 2025 and will conclude on the earlier of the date on which purchases under the bid have been completed and August 21, 2026. The Company may purchase up to a daily maximum of 15,823 common shares (being 25% of the average daily trading volume of 63,293 common shares, for the last six calendar months). The common shares may be purchased for cancellation...
|
|
|
|
|
05.08.25 - 13:33
|
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico (GlobeNewswire EN)
|
|
|
MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT® to COFEPRIS, the Mexican health regulatory agency, for the treatment of Parkinson's disease (PD), post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults. ...
|
|
|
|
|
01.08.25 - 13:33
|
Notice of Knight Therapeutics′ Second Quarter 2025 Results Conference Call (GlobeNewswire EN)
|
|
|
MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2025 financial results on Thursday, August 7, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call....
|
|
|
31.07.25 - 22:33
|
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil (GlobeNewswire EN)
|
|
|
MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
